let data_catalog_data = {"0": {"geo_accession": "GSE97975", "srp_accession": "SRP104270", "data_title": "Extra deep sequencing of GL261 and LLC1 murine cell lines for the purpose of fusion detection", "data_summary": "RNA from GL261 (glioma) and LLC1 (Lewis Lung carcinoma) samples were sequenced at a depth of 142M and 188M paired reads, respectively. Overall design: RNA-sequencing data were used to detect fusions capable of producing proteins containing neoantigens.", "taxon": "Mus musculus", "n_samples": "2", "library_strategy": "RNA-Seq", "cancer_type": "Central Nervous System Neoplasm, Lung Carcinoma", "pmid": ["30674975"], "grant": "CA244687", "earliest_pmid": "30674975", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=30674975", "data_year": 2019, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "1": {"geo_accession": "GSE128476", "srp_accession": "SRP188729", "data_title": "Papillomavirus-Colonized Murine Skin Confers Cancer Resistance", "data_summary": "Herein we hypothesize that there are distinct gene expression changes that occur following MmuPV1 skin colonization that activates antiviral immune mechanisms capable of suppressing tumor growth. Overall design: Total RNA sequencing of skin, tumors and warts from colonized and nieve mice.", "taxon": "Mus musculus", "n_samples": "24", "library_strategy": "RNA-Seq", "cancer_type": "Skin Carcinoma", "pmid": ["31666702"], "grant": "CA233097", "earliest_pmid": "31666702", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=31666702", "data_year": 2019, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "2": {"geo_accession": "GSE147626", "srp_accession": "SRP254303", "data_title": "Deletion of Glutathione S-Transferase Omega 1 Activates Type I Interferon Genes and Downregulates Tissue Factor", "data_summary": "Glutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance. Currently, no small-molecule drug targeting GSTO1 is under clinical development. Using genetic tools, including extensive bioinformatics analysis coupled with CRISPR/Cas9 technologies, we have validated GSTO1 as an impactful target in oncology. Through transcriptional profiling using Bru-seq and RNA-seq coupled with proteomics, we uncovered novel pharmacodynamic markers and cellular pathways regulated by GSTO1. Our CRISPR/Cas9 GSTO1 knockout (KO) cell lines do not form tumors or display growth delay in vivo and form smaller 3D spheroids in vitro. Through multi-omics studies in GSTO1 KO cells, we found a strong positive correlation with cell adhesion molecules and interferon response pathways, and a strong negative correlation with Myc transcriptional signature. Importantly, we also identified several clinically used drugs showing significant synthetic lethality with loss or inhibition of GSTO1. We discovered that tissue factor (gene name, F3) transcription and protein expression are downregulated in response to GSTO1 KO.  Associated with poor patient survival and promotion of tumor progression in multiple cancers, F3 is a known risk factor for metastasis. F3 transcription is under the regulation of IL-1\u00df, whose secretion is decreased upon GSTO1 inhibition, suggesting that IL-1\u00df links GSTO1 expression and F3 transcription. In summary, our results implicate GSTO1 as a therapeutic target in cancer and offer new mechanistic insights into its significant role in cancer progression. Overall design: Cells were lysed with TRIzol\u00ae Reagent (ThermoFisher Scientific, Waltham, MA) at room temperature. RNA was further purified with DirectZol kit (Zymo Research, Irvine, CA). RNA quality was assessed using the TapeStation (Agilent Technologies, Santa Clara, CA). Samples with RINs (RNA Integrity Numbers) of 8 or greater were prepared with TruSeq Stranded mRNA Library Prep (Illumina) per the supplier&#x27;s protocol with 1\u00b5g of RNA and 12 cycles of PCR amplification. Libraries were checked for size on the TapeStation and quantified using the Kapa Biosystems library quantification kit (Illumina). The libraries were barcoded, pooled and sequenced using 50bp paired-end 50bp (U-87 MG, University of Michigan DNA Sequencing Core, MI) and single-end 50bp (HCT116, University of Michgian DNA Sequencing Core, MI) sequencing. Reads were mapped to GRCh38 using STAR v2.5.2 and gene quantifications were calculated using Cufflinks v2.2.1 to quantify refGene annotations. Gene read counts calculated using featureCounts v1.6.1 were used to evaluate differential expression using DESeq2 v1.18.1. Protein coding genes were considered significantly differentially expressed with a mean FPKM &gt; 0.5 and absolute fold change &gt; 1.5 and FDR adjusted p-value &lt; 0.05. All gene readouts where required to be mappable to both an HGNC and Entrez identifier to be considered for gene set enrichment analyses.", "taxon": "Homo sapiens", "n_samples": "12", "library_strategy": "RNA-Seq", "cancer_type": "Solid Tumors", "pmid": ["32571799"], "grant": "DE029255", "earliest_pmid": "32571799", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=32571799", "data_year": 2020, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "3": {"geo_accession": "GSE175744", "srp_accession": "SRP321772", "data_title": "Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model", "data_summary": "DNA mismatch repair deficiency (MMRD) drives microsatellite instability (MSI). Cells with MSI accumulate numerous frameshift mutations. Frameshift mutations affecting cancer-related genes may promote tumorigenesis and, therefore, are shared among independently arising MSI tumors. Consequently, such recurrent frameshift mutations can give rise to shared immunogenic frameshift peptides (FSPs) that represent ideal candidates for a vaccine against MSI cancer. Pathogenic germline variants of mismatch repair genes cause Lynch syndrome (LS), a hereditary cancer syndrome affecting approximately 20-25 million individuals worldwide. LS individuals are at high risk of developing MSI cancer. Previously, we demonstrated safety and immunogenicity of an FSP-based vaccine in a Phase I/IIa clinical trial. However, the cancer-preventive effect of FSP vaccination in the scenario of LS has not been demonstrated so far. Overall design: RNA-seq was performed on tumor and normal intestinal tissue from VcMsh2 mice, treated with NSAID, FSP-vaccination, or combination.", "taxon": "Mus musculus", "n_samples": "69", "library_strategy": "RNA-Seq", "cancer_type": "Gastric Carcinoma", "pmid": ["34224739"], "grant": "CA233056", "earliest_pmid": "34224739", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=34224739", "data_year": 2021, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "4": {"geo_accession": "GSE193725", "srp_accession": "SRP355108", "data_title": "Global evolution of the tumor microenvironment associated with progression from preinvasive/minimally invasive to invasive human lung adenocarcinoma", "data_summary": "To investigate changes in the tumor microenvironment (TME) during lung cancer progression, we interrogate tumors from two computer tomography (CT) defined groups. Pure non-solid (pNS) CT density nodules contain preinvasive/minimally invasive cancers and solid density nodules invasive cancers. Profiling data reveal a dynamic interaction between the tumor and its TME throughout progression. Alterations in genes regulating the extracellular matrix and genes regulating fibroblasts are central at the preinvasive state.  T cell-mediated immune suppression is initiated in preinvasive nodules and sustained with rising intensity through progression to invasive tumors. Reduced T cell infiltration of the cancer cell nests is more frequently associated with preinvasive cancers, possibly until tumor evolution leads to a durable, viable invasive phenotype accompanied by more varied and robust immune suppression. Upregulation of immune checkpoints occurs only in the invasive nodules. Throughout progression an effector immune response is present but is effectively thwarted by the immune-suppressive elements. Overall design: Normal lung, pure non-solid CT scan density adenocarcinoma nodules and solid density nodules were profiles by RNAseq to reveal transcriptome differences associated with progression from normal lung to preinvasive/minimally invasive to invasive lung cancer.", "taxon": "Homo sapiens", "n_samples": "54", "library_strategy": "RNA-Seq", "cancer_type": "Bone Sarcoma, Lung Carcinoma, Bile Duct Carcinoma", "pmid": ["35385730"], "grant": "CA244697", "earliest_pmid": "35385730", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=35385730", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "5": {"geo_accession": "GSE199240", "srp_accession": "SRP365464", "data_title": "Inactivation of the splicing factor RBM10 limits EGFR targeted therapy response in EGFR mutant lung cancer", "data_summary": "Oncogene-driven lung cancers such as those with activating mutations in the epidermal growth factor receptor (EGFR) often harbor additional co-occurring genetic alterations. The significance of most alterations co-occurring with mutant EGFR remains unclear. We report the impact of loss of the mRNA splicing factor RBM10 in human EGFR mutant lung cancer. RBM10 loss decreased EGFR inhibitor efficacy in patient-derived EGFR mutant tumor models. RBM10 regulated mRNA splicing of the mitochondrial apoptotic regulator Bcl-x. Genetic inactivation of RBM10 diminished EGFR inhibitor-mediated apoptosis by altering Bcl-x splicing, decreasing Bcl-xS (pro-apoptotic) and increasing Bcl-xL (anti-apoptotic) levels. Co-inhibition of Bcl-xL and mutant EGFR overcomes resistance induced by RBM10 loss. RBM10 loss was a biomarker of poor response to EGFR inhibitor treatment in clinical samples. Inactivation of the splicing factor RBM10 is a key co-occurring genetic alteration in EGFR mutant tumors that limits EGFR inhibitor efficacy and a potential biomarker of Bcl-xL inhibitor response. Overall design: Examination of 2 different shRBM10 KD in lung cancer PC9 cells.", "taxon": "Homo sapiens", "n_samples": "6", "library_strategy": "RNA-Seq", "cancer_type": "Lung Carcinoma", "pmid": ["35579943"], "grant": "CA274220", "earliest_pmid": "35579943", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=35579943", "data_year": 2022, "network": "ARTNet", "misc_link": "", "misc_type": "", "visportal": ""}, "6": {"geo_accession": "GSE147067", "srp_accession": "SRP252995", "data_title": "Analysis of transcriptional changes induced in PyMT breast tumor by TSLP stimulated CD4+ T cells", "data_summary": "TSLP-stimulated CD4+ T cells block the promotion of breats tumor in mice. In this experiment, we analyze the differences in gene expression profiles of PyMT breast tumors in presence or absence of TSLP-stimulated CD4+ T cell Overall design: Analysis of differentially regulated genes in test group versus control", "taxon": "Mus musculus", "n_samples": "6", "library_strategy": "RNA-Seq", "cancer_type": "Breast Carcinoma", "pmid": ["35657353"], "grant": "CA233097", "earliest_pmid": "35657353", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=35657353", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "7": {"geo_accession": "GSE147106", "srp_accession": "SRP253079", "data_title": "Analysis of transcriptional changes induced in TSLP in CD4+ T cells", "data_summary": "TSLP-stimulated CD4+ T cells block the promotion of breats tumor in mice. In this experiment, we analyze the differences in gene expression profiles of CD4+ T cells in PyMT mice in presence or absence of TSLP-stimulated CD4+ T cell Overall design: Analysis of differentially regulated genes in test group versus control", "taxon": "Mus musculus", "n_samples": "10", "library_strategy": "RNA-Seq", "cancer_type": "Breast Carcinoma", "pmid": ["35657353"], "grant": "CA233097", "earliest_pmid": "35657353", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=35657353", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "8": {"geo_accession": "GSE156117", "srp_accession": "SRP277218", "data_title": "Analysis of the effect of TSLP stimulated CD4+T cells on epigenetic markers in PyMT primary tumors", "data_summary": "TSLP-stimulated CD4+ T cells block the promotion of breast cancer in a spontaneous PyMT mouse model. The goal of this project is to investigate what are the epigenetic changes induced by CD4+ T cells that lead to diminished proliferation of cancer cells Overall design: K14-TSLPtg;PyMT;Rag1KO, and PyMT;Rag1KO mice were injected with wt CD4+ T cells at 4 weeks of age. Tumors were collected when they reached terminal size and tissue was processed for ChIP seq analysis.", "taxon": "Mus musculus", "n_samples": "8", "library_strategy": "ChIP-Seq", "cancer_type": "Breast Carcinoma", "pmid": ["35657353"], "grant": "CA233097", "earliest_pmid": "35657353", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=35657353", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "9": {"geo_accession": "GSE210704", "srp_accession": "SRP390411", "data_title": "Gene expression profile at single cell level of FACS sorted CD8+ T cells from subcutaneous MC38 tumors from WT and Susd2-/-  mice", "data_summary": "Tumor-infiltrating CD8+ T cells are phenotypically heterogeneous with varying degrees of functional defects. We used single cell RNA sequencing (scRNA-seq) to analyze their sex differences. Overall design: Tumor-infiltrating CD8+ T cells in  WT and Susd2-/-   mice were isolated by Fluorescence-Activated Cell Sorting (FACS) from MC38 s.c. tumors on Day 18 post inoculation according to their Cd8a, Trbc1, and Trbc2 expression and analyzed using scRNA-seq", "taxon": "Mus musculus", "n_samples": "8", "library_strategy": "scRNA-Seq", "cancer_type": "Colorectal Carcinoma", "pmid": ["36266363"], "grant": "DE029255", "earliest_pmid": "36266363", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=36266363", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "10": {"geo_accession": "GSE212179", "srp_accession": "SRP394464", "data_title": "Gene expression profile magnetic beads sorted CD8+ T cells from na\u00efve splenocytes and OVA257-264 peptide activated splenocytes from WT and Susd2-/-  OT-I mice", "data_summary": "CD8+ T cells are phenotypically heterogeneous with varying degrees of functional change. We used Bulk RNA sequencing ( Bulk RNA-seq) to analyze the differences betwteen WT and Susd2-/- OT-I mice. Overall design: CD8+ T cells were isolated by the EasySep Mouse CD8+ T Cell Isolation Kit (STEMCELL Technologies) from total splenocytes of either WT or Susd2-/- OT-I mice left untreated or stimulated with OVA257-264 for 3 days. There are 2 samples in WT and 2 samples in Susd2-/- at Day0, and  2 samples  WT and 2 samples in Susd2-/- at Day3.", "taxon": "Mus musculus", "n_samples": "15", "library_strategy": "RNA-Seq", "cancer_type": "Lymphoid Cell Neoplasm", "pmid": ["36266363"], "grant": "DE029255", "earliest_pmid": "36266363", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=36266363", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "11": {"geo_accession": "GSE214000", "srp_accession": "SRP399192", "data_title": "RNA sequencing on the PyMt cell line after culture with test versus control CD4+ T supernatants", "data_summary": "The antitumor immunity mediated by TSLP-stimulated CD4+ T cells in advanced breast cancer is mediated by the induction of a senescent-like phenotype in cancer cells. Overall design: Analysis of differentially regulated genes in test group versus control", "taxon": "Mus musculus", "n_samples": "10", "library_strategy": "RNA-Seq", "cancer_type": "Breast Carcinoma", "pmid": ["36467403"], "grant": "CA233097", "earliest_pmid": "36467403", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=36467403", "data_year": 2022, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "12": {"geo_accession": "GSE237536", "srp_accession": "SRP449872", "data_title": "Effect of carcinogen exposure on gene expression of tumor-associated macrophages", "data_summary": "To investigate the carcinogen exposure in the regulation of macrophages in the tumor microenvironment, we inoculated DMBA3-4 and DMSO3-1 cell lines in Rag1 knockout mice and collect TAMs cells. We then performed gene expression profiling analysis using data obtained from RNA-seq of tumor-associated macrophages  from DMBA3-4 and DMSO3-1 groups. Overall design: Comparative gene expression profiling analysis of RNA-seq data for TAMs from DMBA3-4  and DMSO3-1 groups .", "taxon": "Mus musculus", "n_samples": "12", "library_strategy": "RNA-Seq", "cancer_type": "-", "pmid": ["37843274"], "grant": "CA233097", "earliest_pmid": "37843274", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=37843274", "data_year": 2023, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "13": {"geo_accession": "GSE248378", "srp_accession": "SRP473276", "data_title": "Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial", "data_summary": "Randomized phase II trial patients with early-stage non-small cell lung cancer were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation. We report, based on transcriptome analyses of resected tumors, a correlation between an increase of immune pathway genes and freedom from recurrence. Overall design: RNA-seq studies of resected tumors to identify biomarkers of recurrence in a clinical trial of immune checkpoint blockade therapy in the treatment of non-small cell lung cancer.", "taxon": "Homo sapiens", "n_samples": "29", "library_strategy": "RNA-Seq", "cancer_type": "Lung Carcinoma", "pmid": ["38401548", "38114518"], "grant": "CA244697", "earliest_pmid": "38114518", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=38401548+38114518", "data_year": 2023, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "14": {"geo_accession": null, "srp_accession": "SRP432146", "data_title": "Combined Genomic and Transcriptomic Analysis of Lynch Syndrome Colorectal Neoplasia Identifies Recurrent Shared Mutated Neoantigens for Immune Interception", "data_summary": "Lynch syndrome (LS) carriers develop mismatch repair (MMR) deficient tumors, which generate high loads of neoantigens (neoAgs) and subsequent immune activation. Paired whole exome and transcriptomic sequencing data from colorectal lesions (13 cancers and 61 pre-cancers) of an institutional LS cohort (N=46) were used to identify recurrent and shared neoAgs derived from insertion-deletion mutations in microsatellites. We observed that mutation burden is positively correlated with neoAgs load across different stages of carcinogenesis. A custom computational pipeline was used to rank candidate neoags based on their recurrency and predicted immunogenicity. We demonstrated that 65% of our top predicted neoAgs demonstrated to be immunogenic in vitro via ELISpot assays. Our transcriptomic results revealed increased infiltration of CD8+ and CD4+ T-cells in MMR deficient lesions. Overall, our detailed description of the neoAgs and somatic mutation landscape improve our understanding of MMR deficient carcinogenesis and facilitate the development of future neoAgs-based vaccine strategies for cancer immune interception in LS patients.", "taxon": "Homo sapiens", "n_samples": 131.0, "library_strategy": "WES", "cancer_type": "Sarcoma", "pmid": ["38244726"], "grant": "CA233056", "earliest_pmid": "38244726", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=38244726", "data_year": 2024, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "15": {"geo_accession": "GSE224707", "srp_accession": "SRP421319", "data_title": "Identification and Validation of Frameshift Neoantigens for Mismatch-Repair Deficient Lynch Syndrome", "data_summary": "Lynch syndrome (LS) patients develop DNA mismatch repair deficient tumors which generate high loads of neoantigens (neoAgs), thus constituting a well-defined population that can benefit from cancer immune-interception strategies, including neoantigen-based vaccines. Using paired whole-exome sequencing and mRNAseq of colorectal cancers (CRC) (n=13) and pre-cancers (n=61) from our LS patient cohort (N=46), we performed in-silico prediction and immunogenicity ranking of highly recurrent frameshift-neoags, followed by their in-vitro validation. We described the somatic mutation landscape in all cancers and pre-cancers, and showed that mutation burden is positively correlated with neoAgs load. Furthermore, our in-vitro validation showed a 65% validation rate of our top 100 predicted neoags. Consistent with neoAgs burden, our transcriptomic results revealed increased infiltration of CD8+ and CD4+ T-cells in microsatellite unstable samples. Overall, our neoAgs catalog and all other findings, improve our understanding of cancer development in LS and guide us towards the advancement of immunoprevention vaccine strategies. Overall design: All patients included in this study had a confirmed diagnosis of Lynch Syndrome (n = 46) and provided written informed consent at The University of Texas MD Anderson Cancer Center (MDACC). All samples were obtained from study participants through an Institutional Review Board (IRB) approved protocol at MDACC (Protocol PA12-0327). A set of 74 flash-frozen or formalin-fixed paraffin embedded (FFPE) tissue biopsies from polyps or tumors of the lower gastrointestinal tract, with matching normal mucosa and peripheral blood, were collected from 46 LS patients who came to MDACC for a standard of care surveillance colonoscopy. The pathological diagnosis of all tissue samples was confirmed by a gastrointestinal pathologist (M.W.T) at MDACC. Samples were classified as inflammatory polyps (IP), hyperplastic polyps (HP), sessile serrated adenomas (SSA), adenomatous polyps (AP), which included tubular as well as tubullovillous adenomas, and adenocarcinomas, based on pathological diagnosis. Depending on the level of high-grade dysplasia samples were classified into different tissue categories that included pre-cancers, defined as pre-malignant lesions with low or no level of dysplasia, advanced pre-cancers, defined as pre-malignant lesions with high level of dysplasia, and cancers.  DNA and RNA were extracted from all flash-frozen and FFPE tissue samples using the Quick-DNA/RNA Miniprep Kit (Zymo Research, CA) and AllPrep DNA/RNA FFPE Kit (Qiagen, MD), respectively. Genomic DNA was obtained from peripheral blood using Gentra Puregene Blood Kit (Qiagen).", "taxon": "Homo sapiens", "n_samples": "34", "library_strategy": "RNA-Seq", "cancer_type": "Colorectal Carcinoma", "pmid": ["38244726"], "grant": "CA233056", "earliest_pmid": "38244726", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=38244726", "data_year": 2024, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "16": {"geo_accession": "GSE253564", "srp_accession": "SRP484548", "data_title": "Features associated with enhanced proliferation define lung tumors that respond to dual immune checkpoint and radiation therapy", "data_summary": "In a randomized phase II trial, patients with early-stage non-small cell lung cancer were were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation. We conducted an analysis of the gene expression profiles of treatment-naive tumors from these patients and identified a 140-gene signature that was correlated with a positive response to the dual therapy. This signature showed enrichment in genes associated with cell proliferation. Overall design: RNA-seq studies of resected tumors to identify biomarkers of response in a clinical trial of immune checkpoint blockade therapy in the treatment of non-small cell lung cancer.", "taxon": "Homo sapiens", "n_samples": "32", "library_strategy": "RNA-Seq", "cancer_type": "Lung Carcinoma", "pmid": ["38401548"], "grant": "CA244697", "earliest_pmid": "38401548", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=38401548", "data_year": 2024, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "17": {"geo_accession": "GSE262030", "srp_accession": "SRP496707", "data_title": "Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumor", "data_summary": "Neurofibromatosis Type 1 (NF1) is a common cancer predisposition syndrome, caused by heterozygous loss of function mutations in the tumor suppressor gene NF1. Individuals with NF1 develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell linage after somatic loss of the wild type NF1 allele, some of which progress further to malignant peripheral nerve sheath tumors (MPNST). There is only one FDA approved targeted therapy for symptomatic plexiform neurofibromas and none approved for MPNST. The genetic basis of NF1 syndrome makes associated tumors ideal for using synthetic drug sensitivity approaches to uncover vulnerabilities. We developed a drug discovery pipeline to identify therapeutics for NF1-related tumors using isogeneic pairs of NF1 proficient and deficient immortalized human Schwann cells. We utilized these in a large-scale high throughput screen (HTS) for drugs that preferentially kill NF1 deficient cells, which identified 23 compounds capable of killing NF1 deficient Schwann cells with selectivity. Multiple hits from this screen clustered into classes defined by method of action. Four clinically interesting drugs from these classes were tested in vivo using both a genetically engineered mouse model of high-grade peripheral nerve sheath tumors and human MPNST xenografts. All trugs tested showed single agent efficacy in these models as well as significant synergy when used in combination with the MEK inhibitor selumetinib. This HTS platform has yielded novel therapeutically relevant compounds for the treatment of NF1-associated tumors and can serve as a tool to rapidly evaluate new compounds and combinations in the future. Overall design: To understand the transcriptional response to a variety of drug treatments in MPNST cells, we treated S462TY cells with a variety of drug treatments and combinations. RNAseq was captured at both 2 hour and 24 hour timepoints for Digoxin, Rigosertib, and Selumetinib, as well as combinations of Digoxin with Selumetinib and Rigosertib with Selumetiinib. DMSO (vehicle) controls were captured for both time points. Untreated cell line controls were captured at 0, 2, and 24 hour timepoints.", "taxon": "Homo sapiens", "n_samples": "51", "library_strategy": "RNA-Seq", "cancer_type": "Nervous System Neoplasm", "pmid": ["38585724", "41036607"], "grant": ";CA244687", "earliest_pmid": "38585724", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=38585724+41036607", "data_year": "", "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "18": {"geo_accession": "GSE220667", "srp_accession": "SRP412399", "data_title": "PyMT breast cancer treatment with ethanol versus calcipotriol", "data_summary": "To find which signaling affects the therapy of calcipotriol in breast cancer therapy Overall design: Topical treatment of PyMT mammary breast cancer with ethanol or calcipotriol", "taxon": "Mus musculus", "n_samples": "8", "library_strategy": "RNA-Seq", "cancer_type": "Breast Carcinoma", "pmid": ["39782693"], "grant": "CA233097", "earliest_pmid": "39782693", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=39782693", "data_year": 2025, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "19": {"geo_accession": "GSE306088", "srp_accession": "SRP610542", "data_title": "Microbiome Modulation Uncouples Efficacy and Toxicity Induced by Programmed Death-1/Programmed Death-Ligand1 Blockade in multiple myeloma", "data_summary": "Intestinal microbiota and gut-born T helper-17 (Th17) lymphocytes may act as drivers of smoldering multiple myeloma (SMM) to MM evolution. We demonstrate here that administering the human commensal Prevotella melaninogenica to transgenic Vk*MYC mice affected by Early-MM, mimicking human SMM, significantly delayed evolution to full-blown MM. Mechanistically, P. melaninogenica increased the production of short-chain fatty acids (SCFAs), preventing skew of dendritic cells towards a pro-Th17 phenotype and accumulation of Th17 cells in the bone marrow of treated mice. P. melaninogenica or butyrate synergized with anti-PD-L1 antibodies by restraining Th17 cell expansion while unleashing immune checkpoint blockade (ICB)-induced effector CD8+ T cells. P. melaninogenica also attenuated IL-17-mediated skin lesions that mimicked ICB-induced immune-related adverse events. Thus, modulation of the gut microbiota or SCFAs administration with or without ICB might represent treatment options for patients affected by plasma cell dyscrasias and other hematologic or solid tumors where IL-17 acts as driving force. Overall design: Bulk RNA-Seq of  Bone Marrow Dendritic Cells (BMDCs) cultured either with P. melaninogenica (PM) or P. heparinolytica (PH).", "taxon": "Mus musculus", "n_samples": "8", "library_strategy": "RNA-Seq", "cancer_type": "Gastric Carcinoma, Lymphoid Cell Neoplasm", "pmid": ["41285849"], "grant": "CA290468", "earliest_pmid": "41285849", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=41285849", "data_year": 2025, "network": "CIP-NET", "misc_link": "", "misc_type": "", "visportal": ""}, "20": {"geo_accession": "GSE311602", "srp_accession": null, "data_title": "A High-Fiber Plant-Based Diet Delays Progression to Myeloma in Precursor Disorders", "data_summary": "Consumption of a western diet and high body mass index (BMI) are risk factors for progression from pre-malignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber plant-based diet to patients with myeloma precursor states and elevated BMI. The intervention was feasible, improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease-progression trajectory improved in two participants and was stable in others. In Vk*MYC+/- mice modeling the myeloma-precursor state, a high-fiber diet delayed disease progression through improved microbiome composition and increased short-chain fatty acid production that reinvigorated anti-tumor immunity and inhibited tumor growth. These effects resulted from fiber consumption and were independent from calorie restriction-induced weight loss.", "taxon": "Homo sapiens", "n_samples": "24", "library_strategy": "Other", "cancer_type": "Lymphoid Cell Neoplasm", "pmid": ["41342739"], "grant": "CA290468", "earliest_pmid": "41342739", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=41342739", "data_year": 2026, "network": "CIP-NET", "misc_link": "", "misc_type": "", "visportal": ""}, "21": {"geo_accession": "GSE310041", "srp_accession": null, "data_title": "Bulk RNA-Seq of head and neck squamous cell carcinomas", "data_summary": "To substantiate the physiological relevance of the glutamine-BATF2 pathway, we performed bulk RNA-Seq on 15 HNSCC specimens. Then, we performed a correlation analysis between BATF2-IFN-I pathway genes and glutamine metabolism markers.", "taxon": "Homo sapiens", "n_samples": "30", "library_strategy": "RNA-Seq", "cancer_type": "Head and Neck Carcinoma", "pmid": ["41457098"], "grant": "DE029255", "earliest_pmid": "41457098", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=41457098", "data_year": 2025, "network": "IOTN", "misc_link": "", "misc_type": "", "visportal": ""}, "22": {"geo_accession": "GSE301392", "srp_accession": null, "data_title": "Elucidating the Mechanisms of SA-4-1BBL Immunoprevention Through Advanced Informatics Approaches", "data_summary": "Cancer immunoprevention leverages the immune system\u2019s surveillance mechanisms to mitigate tumor development. Vaccines constituting a tumor antigen and an immune adjuvant are perceived immunoprevention modalities. However, relevant tumor antigens are unknown for non-viral cancers, which constitute the majority of human cancers. Our group has recently shown that SA-4-1BBL, a novel oligomeric recombinant agonist of CD137 costimulatory molecule, as a single agent, has robust immunoprevention efficacy against various tumor types. In marked contrast, agonistic antibodies to CD137 lacked such function. This study employs advanced informatics approaches for analyzing bulk RNA sequencing (RNA-seq) transcriptomics data to elucidate the molecular mechanisms driving SA-4-1BBL\u2019s immunoprevention efficacy. Mice were treated subcutaneously with SA-4-1BBL or an agonistic antibody and injection site (IS) tissue and draining lymph nodes (LN) were analyzed for differentially expressed genes (DEGs). Our findings reveal that SA-4-1BBL induces a compartmentalized and temporally dynamic immune program, characterized by early effector activation at IS and sustained immune regulation in draining LN. K-means clustering of 4,564 DEGs identified 8 functionally distinct clusters, with IS-enriched clusters (1 and 4) upregulating effector genes such as Cd28, Klra1, Cd4, Cd40, and Cd40l, supporting CD4+ T and NK cell activation. In contrast, LN-dominant clusters (2 and 5) were enriched for regulatory genes (Tnfaip3, Irf5, Col1a2), implicating roles in tissue remodeling and long-term immune memory. Compared to agonistic antibody, SA-4-1BBL elicited a more selective and durable activation of adaptive immune pathways, including TCR signaling, Th1/Th2 differentiation, and NK cytotoxicity, while avoiding systemic inflammation. Agonistic antibody, in contrast, activated broader innate inflammatory programs, including Toll-like receptor and neurodegeneration-linked pathways. IMPRes analysis revealed that SA-4-1BBL engages sequential immune-regulatory circuits centered on Stat1, Cd247, and Ifng, and modulates the CD151\u2013TGF-\u03b2 axis, offering novel mechanistic insight into its immune-balancing effects. These findings define a compartmentalized immune architecture that underlies SA-4-1BBL\u2019s ability to provide safe, long-lasting cancer immunoprevention. Our study highlights the value of applying comprehensive informatics techniques in decoding the spatial and functional complexity of tissue-specific immune programming.", "taxon": "Mus musculus", "n_samples": "62", "library_strategy": "Other", "cancer_type": "-", "pmid": ["41750322"], "grant": "CA290305", "earliest_pmid": "41750322", "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=41750322", "data_year": 2026, "network": "CIP-NET", "misc_link": "", "misc_type": "", "visportal": ""}, "23": {"geo_accession": "", "srp_accession": "", "dbgap_id": "phs002818.v1.p1", "misc_link": "", "misc_type": "", "data_title": "Intercepting Progression from Pre-Invasive to Invasive Lung Adenocarcinoma", "data_summary": "An improved understanding of the biology of lung cancer is needed to intercept the disease at an early point in its progression. In this project we have used multidimensional methods to profile the tumor microenvironment (TME) and to determine the crosstalk between cancer cells and the TME in pre-invasive to invasive human lung non-solid adenocarcinomas. Comparative analysis of the cellular and molecular events associated with the distinct histological stages will lead to identification of the critical events triggering progression and thereby identify targets to intercept disease progression. The data being submitted represents the genomic profiles of patient samples with pre-invasive and invasive human lung adenocarcinomas.", "taxon": "Homo sapiens", "n_samples": "", "library_strategy": "WES", "cancer_type": "Lung Carcinoma", "earliest_pmid": 35385730, "pmid_link": "https://pubmed.ncbi.nlm.nih.gov/?term=35385730", "pmid": "['35385730']", "grant": "CA244697;CA244697", "data_year": 2022, "include_in_cipnet": "yes", "network": "IOTN", "visportal": ""}};